Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Oncology

• Publication date

  2001-01-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2001.19.2.584PMID 11208854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma.

  2000cited by this paper
• Singlet molecular oxygen-mediated photo-oxidation of tetracyclines: kinetics, mechanism and microbiological implications.

  1998cited by this paper
• Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis

  1998cited by this paper
• Potential Application of a Chemically Modified Non-Antimicrobial Tetracycline (CMT-3) Against Metastatic Prostate Cancer

  1998cited by this paper
• Inhibition of MMP Synthesis by Doxycycline and Chemically Modified Tetracyclines (CMTs) in Human Endothelial Cells

  1998cited by this paper
• Tetracycline-Based MMP Inhibitors Can Prevent Fibroblast-Mediated Collagen Gel Contraction In Vitro

  1998cited by this paper
• Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2.

  1998cited by this paper
• Tetracycline Derivatives Induce Apoptosis Selectively in Cultured Monocytes and Macrophages but not in Mesenchymal Cells

  1998cited by this paper
• Accelerated titration designs for phase I clinical trials in oncology.

  1997cited by this paper
• Changing views of the role of matrix metalloproteinases in metastasis.

  1997cited by this paper
• Comparative safety of tetracycline, minocycline, and doxycycline.

  1997cited by this paper
• Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity.

  1996cited by this paper
• Chemically modified tetracyclines inhibit inducible nitric oxide synthase expression and nitric oxide production in cultured rat mesangial cells.

  1996cited by this paper
• Clinical Applications of Research on Angiogenesis

  1995cited by this paper
• Influence of ethanol ingestion on tetracycline kinetics.

  1995cited by this paper
• Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis.

  1995cited by this paper
• Procollagenase Is Reduced to Inactive Fragments upon Activation in the Presence of Doxycycline a

  1994cited by this paper
• Phototoxic eruptions due to doxycycline—a dose‐related phenomenon

  1993cited by this paper
• Reactive oxygen species activate and tetracyclines inhibit rat osteoblast collagenase

  1993cited by this paper
• Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs.

  1991cited by this paper
• Metalloproteinases and cancer invasion.

  1990cited by this paper
• A Study of the Interaction between Oxytetracycline and Pyridostigmine

  1988cited by this paper
• Pharmacokinetics and bioavailability of doxycycline in humans.

  1986cited by this paper
• Tetracyclines inhibit tissue collagenases. Effects of ingested low-dose and local delivery systems.

  1985cited by this paper
• Pharmacokinetics of lymecycline and doxycycline in serum and suction blister fluid.

  1985cited by this paper
• Further evidence that tetracyclines inhibit collagenase activity in human crevicular fluid and from other mammalian sources.

  1985cited by this paper
• Tetracyclines Inhibit Tissue Collagenases: Effects of Ingested Low-Dose and Local Delivery Systems.

  1985cited by this paper
• Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia.

  1985cited by this paper
• Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease.

  1984cited by this paper
• Mechanism of tetracycline phototoxicity.

  1984cited by this paper
• Mechanism of tetracycline phototoxicity.

  1984cited by this paper
• Tetracyclines inhibit tissue collagenase activity. A new mechanism in the treatment of periodontal disease.

  1984cited by this paper
• Minocycline reduces gingival collagenolytic activity during diabetes. Preliminary observations and a proposed new mechanism of action.

  1983cited by this paper
• Oxidation photosensitized by tetracyclines.

  1977cited by this paper
• Bioavailability of Tetracycline and Doxycycline in Fasted and Nonfasted Subjects

  1977cited by this paper
• Clinical pharmacologic studies with minocycline.

  1971cited by this paper
• Influence of repetitive dosing of tetracyclines on biologic half‐life in serum

  1969cited by this paper
• Sideroblastic Anaemia in Man: Observations on Seventy Cases

  1965cited by this paper
• Antituberculous Drugs and Sideroblastic Anaemia

  1965cited by this paper
• Comparative Serum Binding, Distribution and Excretion of Tetracycline and a New Analogue, Methacycline

  1962cited by this paper
• Abnormal ("ringed") sideroblasts in various hematologic and non-hematologic disorders.

  1961cited by this paper
• Effect of chloramphenicol on erythropoiesis.

  1961cited by this paper
• Demethylchlortetracycline; a new tetracycline antibiotic that yields greater and more sustained antibacterial activity.

  1958cited by this paper

• Atypical tetracyclines promote longevity and ferroptotic neuroprotection via translation attenuation

  2026cites this paper
• Matrix Metalloproteinase Inhibition in Melanoma

  2026cites this paper
• An in vitro model to measure the strength and stiffness of the extracellular matrix synthesized de novo by human fibroblasts

  2025cites this paper
• Matrix Metalloproteinases and Their Inhibitors in the Pathogenesis of Epithelial Differentiation, Vascular Disease, Endometriosis, and Ocular Fibrotic Pterygium

  2025cites this paper
• Tumor biomarkers for diagnosis, prognosis and targeted therapy

  2024cites this paper
• Extracellular Matrix as a Target in Melanoma Therapy: From Hypothesis to Clinical Trials

  2024cites this paper
• The Role of MMP-9 and MMP-9 Inhibition in Different Types of Thyroid Carcinoma

  2023cites this paper
• Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.

  2022cites this paper
• Doxycycline inhibits the progression of metastases in early-stage osteosarcoma by downregulating the expression of MMPs, VEGF and ezrin at primary sites.

  2022cites this paper
• The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance

  2022cites this paper
• An in silico study on reproposing eravacycline as an MMP inhibitor

  2022cites this paper
• Combined Radiochemotherapy: Metalloproteinases Revisited

  2021cites this paper
• Inhibitory Effects of Doxycycline on Tumor Progression In vitro and on Metastases in Early-Stage Osteosarcoma Xenografts Mice.

  2021cites this paper
• Repositioning Adequate Antibiotics to Treat/Cure the Coronavirus Disease 2019 (COVID-19): Current Treatments and Future Directions

  2021cites this paper
• The Chemically-Modified Tetracycline COL-3 and Its Parent Compound Doxycycline Prevent Microglial Inflammatory Responses by Reducing Glucose-Mediated Oxidative Stress

  2021cites this paper
• The Pharmacological TAILS of Matrix Metalloproteinases and Their Inhibitors

  2020cites this paper
• Synthesis and Antitumor Activity of Doxycycline Polymeric Nanoparticles: Effect on Tumor Apoptosis in Solid Ehrlich Carcinoma

  2020cites this paper
• The past, present and future perspectives of matrix metalloproteinase inhibitors.

  2019cites this paper
• Periodontal therapeutics: Current host‐modulation agents and future directions

  2019cites this paper
• Tetracyclines: Insights and Updates of their Use in Human and Animal Pathology and their Potential Toxicity

  2019cites this paper
• Mechanism and Inhibition of Matrix Metalloproteinases.

  2019cites this paper
• Mitochondria as oncotarget: a comparison between the tetracycline analogs doxycycline and COL-3

  2018cites this paper
• Accelerated wound healing and its promoting effects of biomimetic collagen matrices with siderophore loaded gelatin microspheres in tissue engineering.

  2018cites this paper
• Targeting Mammalian Translational Inhibition with Tetracyclines.

  2018cites this paper
• Antenna effect and phosphorescence spectra to find the location of drug tetracycline in bovine β-lactoglobulin A

  2018cites this paper
• Tetracyclines Modify Translation By Targeting Key Human rRNA Substructures

  2018cites this paper
• Zymography

  2017cites this paper
• Zymography as a Research Tool in the Study of Matrix Metalloproteinase Inhibitors.

  2017cites this paper
• Role of Metalloproteinases in Melanoma Growth and Progression

  2017cites this paper
• Chapter 1 – Angiogenesis and Anti-Angiogenesis Strategies in Cancer

  2017cites this paper
• Impact of metal coordination on the antibiotic and non-antibiotic activities of tetracycline-based drugs

  2016cites this paper
• Matrix metalloproteinase 2 fused to GFP, expressed in E. coli, successfully tracked MMP-2 distribution in vivo.

  2016cites this paper
• Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers

  2016cites this paper
• N-acetylglucosaminyl 1-phosphate transferase: an excellent target for developing new generation breast cancer therapeutic.

  2015cites this paper
• Anti-malarials are anti-cancers and vice versa - one arrow two sparrows.

  2015cites this paper
• Biochemical Roles of Eukaryotic Cell Surface Macromolecules

  2015cites this paper
• eview nti-malarials are anti-cancers and vice versa – One arrow two parrows hanakya

  2015cites this paper
• Évaluation de ligands pour l’imagerie moléculaire de la néoangiogenèse tumorale

  2015cites this paper
• Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil

  2015cites this paper
• La doxycycline ou comment faire du neuf avec du vieux

  2014cites this paper
• [Doxycycline or how to create new with the old?].

  2014cites this paper
• Is there new hope for therapeutic matrix metalloproteinase inhibition?

  2014cites this paper
• Matrix metalloproteinases are involved in cardiovascular diseases.

  2014cites this paper
• Non-Antibacterial Implications of Tetracyclines in the Management of Periodontitis: An Update

  2013cites this paper
• Review of Cancer – Associated Fibroblasts and Therapiesthat Interfere with Their Activity

  2013cites this paper
• Survey of Anti-angiogenesis Strategies

  2013cites this paper
• mAtri X metA lloprote A se 9 A nd remodeling A fter myoc A rdi A l infA rction

  2013cites this paper
• Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.

  2013cites this paper
• Potential Clinical Applications of Matrix Metalloproteinase Inhibitors and their Future Prospects

  2013cites this paper
• Angiogenesis in Brain Tumors

  2013cites this paper
• Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment.

  2012cites this paper
• Identifying and Targeting Molecular Deregulations in Uterine Leiomyosarcoma: A Role for mTOR Inhibition-Based Combination Therapies

  2012cites this paper
• MMPs in ovarian cancer as therapeutic targets.

  2012cites this paper
• Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase.

  2011cites this paper
• Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS).

  2011cites this paper
• Increased immunoreactivity of membrane type‐1 matrix metalloproteinase (MT1‐MMP) and β‐catenin in high‐risk basal cell carcinoma

  2011cites this paper
• Antimicrobial and non-antimicrobial tetracyclines in human cancer trials.

  2011cites this paper
• Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas

  2011cites this paper
• Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic.

  2011cites this paper
• Matrix metalloproteinase inhibitors: a review on bioanalytical methods, pharmacokinetics and metabolism.

  2011cites this paper
• Role of Angiogenesis and Microenvironment in Melanoma Progression

  2011cites this paper
• Molecular-targeted therapy for cancer.

  2010cites this paper
• Proteases and Therapeutic Approaches of Bone Tumors

  2010cites this paper
• Biomarkers for diagnosis in thoracic aortic disease: PRO.

  2010cites this paper
• Angiogenesis and Progression in Human Melanoma

  2010cites this paper
• From Melanocyte to Malignant Metastatic Melanoma

  2010cites this paper
• Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).

  2010cites this paper
• Matrix metalloproteinases in the pathophysiology and progression of gynecological malignancies: could their inhibition be an effective therapeutic approach?

  2009cites this paper
• MMP Inhibitor Clinical Trials – The Past, Present, and Future

  2008cites this paper
• Clinical approaches toward tumor angiogenesis: past, present and future.

  2008cites this paper
• CMT3 alters mitochondrial function in murine osteoclast lineage cells.

  2008cites this paper
• Phase 1/2 trial of BMS‐275291 in patients with human immunodeficiency virus‐related Kaposi sarcoma

  2008cites this paper
• Progress in the development of matrix metalloproteinase inhibitors.

  2008cites this paper
• Antiangiogenic drugs: current knowledge and new approaches to cancer therapy.

  2008cites this paper
• Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.

  2008cites this paper
• A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

  2007cites this paper
• PtdIns-4,5-P2 as a potential therapeutic target for pathologic angiogenesis

  2007cites this paper
• Angiogenesis in melanoma.

  2007cites this paper
• Early Clinical Studies on Target Specific Anticancer Agents

  2006cites this paper
• Matrix metalloproteinases: role in arthritis.

  2006cites this paper
• Influence of the microenvironment on melanoma cell fate determination and phenotype.

  2006cites this paper
• Accelerated Titration Designs

  2006cites this paper
• The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases

  2006cites this paper
• Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches.

  2006cites this paper
• Tetracyclines: nonantibiotic properties and their clinical implications.

  2006cites this paper
• Anti‐angiogenic drugs: from bench to clinical trials

  2006cites this paper
• Tetracycline analogues (doxycycline and COL‐3) induce caspase‐dependent and ‐independent apoptosis in human colon cancer cells

  2006cites this paper
• Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer

  2006cites this paper
• Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.

  2006cites this paper
• Matrix Metalloproteinases in Thoracic Aortic Aneurysm Disease

  2006cites this paper
• A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection.

  2005cites this paper
• Significant Intestinal Excretion, One Source of Variability in Pharmacokinetics of COL-3, a Chemically Modified Tetracycline

  2005cites this paper
• A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell–microenvironment interactions

  2005cites this paper
• MAST CELLS AND SYNOVIAL FIBROBLASTS AS NOVEL TARGETS FOR ANTIRHEUMATIC THERAPY

  2005cites this paper
• A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors

  2005cites this paper
• Antiangiogenesis: a possible treatment option for prostate cancer?

  2005cites this paper
• Angiogenesis and hemostasis in hematological neoplasias.

  2005cites this paper
• Chemically modified tetracyclines induce apoptosis in cultured mast cells.

  2005cites this paper
• Metalloproteinase Inhibitors, Nonantimicrobial Chemically Modified Tetracyclines, and Ilomastat Block Bacillus anthracis Lethal Factor Activity in Viable Cells

  2005cites this paper
• Use of Tetracyclines for Bone Metastases

  2005cites this paper